BUY NOW For Sale 70%!
buy viagra

Wechselwirkung pille azithromycin 500

  • Akita H, Sato Y, Iwata S, Sunakawa K. Laboratory and clinical studies on clarithromycin in pediatrics. Japanese Journal of Antibiotics 42: 263–280, 1989Google Scholar

  • wechselwirkung pille azithromycin 500
  • Aonuma S, Tokue Y, Kitamura N, Honda Y, Ono R, et al. TE-031 (A-56268) in treatment of respiratory tract infections. Chemotherapy 36: 549–552, 1988Google Scholar

  • Alder J, Hutch T, pille Mitten M, Clement J. The successful treatment of Lyme Disease with clarithromycin in hamsters. 5th International Conference on the Macrolides, Azalides and Strep-togramins, Santa Fe, New Mexico, 1992Google Scholar

  • Aidons PM. A comparison of clarithromycin with ampicillin in the treatment of outpatients with acute bacterial exacerbation of chronic bronchitis. Journal of Antimicrobial Chemotherapy 27(Suppl. A): 101–108, 1991CrossRefGoogle Scholar

  • Anderson G, Esmonde TS, Coles S, Macklin J, Carnegie C. A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia. Journal of Antimicrobial Chemotherapy 27(Suppl. A): 117–124, 1991PubMedCrossRefGoogle Scholar

  • Anderson R, Joone G, van Rensburg CEJ. An in vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent. Journal of Antimicrobial Chemotherapy 22: 923–933, 1988PubMedCrossRefGoogle Scholar

  • Araujo FC, Prokocimer P, Remington JS. Clarithromycin-mi-nocycline is synergistic in a murine model of toxoplasmosis. Journal of Infectious Diseases 165: 788, 1992PubMedCrossRefGoogle Scholar

  • Baba S, Soyano K, Kawamura S, Fujimaki Y, Maruo T, et al. Clinical evaluation of TE-031 in the treatment of paranasal sinusitis. Jibi to Rinsho 35: 156–165, 1989aGoogle Scholar

  • Baba S, Soyano K, Takasaka T, Kobayashi T, Sasaki Y, et al. Evaluation of TE-031 in the treatment of suppurative otitis media: results of a double-blind comparative clinical study with josamycin. Jibi to Rinsho 35: 113–133; 1989bGoogle Scholar

  • Bachand Jr RT. Comparative study of clarithromycin and ampicillin in the treatment of patients with acute bacterial exacerbations of chronic bronchitis. Journal of Antimicrobial Chemotherapy 27(Suppl. A): 91–100, 1991aPubMedCrossRefGoogle Scholar

  • Bachand Jr RT. A comparative study of clarithromycin and penicillin VK in the treatment of outpatients with streptococcal pharyngitis. Journal of Antimicrobial Chemotherapy 27(Suppl. A): 75–82, 1991bPubMedCrossRefGoogle Scholar

  • Back DJ, Grimmer SFM, Orme ML’E, Proudlove C, Mann RD, et al. Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anti-convulsants and antibiotics. British Journal of Clinical Pharmacology 25: 527–532, 1988PubMedCrossRefGoogle Scholar

  • Barry AL, Thornsberry C, Jones RN. In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin. Antimicrobial Agents and Chemotherapy 31: 343–345, 1987PubMedCrossRefGoogle Scholar

  • Barry AL, Fernandes PB, Jorgensen JH, Thornsberry C, Hardy DJ et al. Variability of clarithromycin and erythromycin susceptibility tests with Haemophilus influenzae in four different broth media and correlation with the standard disk diffusion test. Journal of Clinical Microbiology 26: 2415–2420, 1988aPubMedGoogle Scholar

  • Barry AL, Jones RN, Thornsberry C. In vitro activities of azith-romycin (CP 62, 993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. Antimicrobial Agents and Chemotherapy 32: 752–754, 1988bPubMedCrossRefGoogle Scholar

  • Barry AL, Jorgensen JH, Hardy DJ. Reproducibility of disc susceptibility tests with Haemophilus influenzae. Journal of Antimicrobial Chemotherapy 27: 295–301, 1991PubMedCrossRefGoogle Scholar

  • Bedos JP, Rajagopalan P, Azoulay-Dupois E, Polianski J, Poci-dalo JJ, et al. Individual in vivo potency of clarithromycin (A-56268) and its main human metabolite (A-62671) in mouse pneumococcal experimental pneumonia. International Congress on Antimicrobial Agents and Chemotherapy, 1989Google Scholar

  • Benson CA, Segreti J, Beaudette FE, Hines DW, Goodman LJ, et al. In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected Gram-positive and Gram-negative organisms. Antimicrobial Agents and Chemotherapy 31: 328–330, 1987aPubMedCrossRefGoogle Scholar

  • Benson C, Segreti J, Kessler H, Hines D, Goodman L, et al. Comparative in vitro activity of A-56268 (TE-031) against Gram-positive and Gram-negative bacteria and Chlamydia tracho-matis. European Journal of Clinical Microbiology and Infectious Diseases 6: 173–178, 1987bCrossRefGoogle Scholar

  • Bergeron MG, Bernier M, L’Eciyer J. In vitro activity of clarithromycin (A-56268) combined with its 14-OH metabolite (A-62761) against 203 strains of Haemophilus influenzae. 30th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Georgia, October, 1990Google Scholar

  • Bergeron MG, Bernier M, LśEciyer J. In vitro activity of clarithromycin (C) and its 14-Hydroxy metabolite aginst β-lactamase positive and negative strains of Haemophilus influenzae. 1st International Conference on the Macrolides, Azalides and Strptogramins. Santa Fe, New Mexico, 1992Google Scholar

  • Brismar BO, Edlund C, Nord CE. Comparative effects of clarithromycin and erythromycin on the normal intestinal micro-flora. Scandinavian Journal of Infectious Diseases 23: 635–642, 1991PubMedCrossRefGoogle Scholar

  • Brown BA, Wallace Jr RJ, Onyi GO, De Rosas G, Wallace III RJ. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrobial Agents and Chemotherapy 36: 180–184; 1992PubMedCrossRefGoogle Scholar

  • Bryan JP, Waters C, Sheffield J, Wagner KF. In vitro activity of tosufloxacin (A-60969) and clarithromycin (A-56268, TE-031) against resistant Haemophilus influenzae, Streptococcus pneu-moniae and Branhamella catarrhalis isolates. New Antimicrobial Agents 9: 361–365, 1990Google Scholar

  • Cassell GH, Drnec J, Waites KB, Pate MS, Duffy LB, et al. Efficacy of clarithromycin against Mycoplasma pneumoniae. Journal of Antimicrobial Chemotherapy 27(Suppl. A): 47–59, 1991PubMedCrossRefGoogle Scholar

  • Chin N-X, Neu NM, Labthavikul P, Saha G, Neu HC. Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria. Antimicrobial Agents and Chemotherapy 31: 463–466, 1987PubMedCrossRefGoogle Scholar

  • Chonabayashi N, Noguchi M, Yoshimura K, Nakatani T, Nakamori Y, et al. Clinical study of TE-031 (A-56268) in the treatment of 17 patients with respiratory infections. Chemotherapy 36: 586–593, 1988Google Scholar

  • Chu SY, Deaton R, Cavanaugh J. Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrobial Agents and Chemotherapy 36: 1147–1150, 1992aPubMedCrossRefGoogle Scholar

  • Chu SY, Park Y, Locke C, Wilson DS, Cavanaugh JC. Drug-food interaction potential of clarithromycin, a new macrolide antimicrobial. Journal of Clinical Pharmacology 32: 32–36; 1992bPubMedGoogle Scholar

  • Chu SY, Sennello LT, Sonders RC. Simultaneous determination of clarithromycin and 14(R)-hydroxyclarithromycin in plasma and urine using high performance liquid chromatography with electrochemical detection. Journal of Chromatography 571: 199–208, 1991PubMedCrossRefGoogle Scholar

  • Chu SY, Wilson DS, Eason C, Deaton RL, Cavanaugh J, et al. Single- and multi-dose pharmacokinetics of clarithromycin. 30th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Georgia, October, 1990Google Scholar

  • Chu SY, Wilson DS, Guay DRP, Craft C. Clarithromycin pharmacokinetics in healthy young and elderly volunteers. Journal of Clinical Pharmacology, in press, 1992cGoogle Scholar

  • Craft JC. Clarithromycin vs cephalosporin therapy for the treatment of H, influenzae bronchitis. 1st International Conference on the Macrolides, Azalides and Streptogramins, Santa Fe, New Mexico, 1992Google Scholar

  • Craft JC, Gupta S, Drnec J et al. Treatment of streptococcal pharyngitis: a comparison of clarithromycin vs penicillin VK. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, Georgia, 1990Google Scholar

  • Dabernat H, Delmas C, Seguy M, Fourtillan JB, Girault J, et al. The activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae, determined by in-vitro and serum bactericidal tests. Journal of Antimicrobial Chemotherapy 27(Suppl. A): 19–30, 1991PubMedCrossRefGoogle Scholar

  • Dautzenberg B, St Marc T, Chauvin JP, Hazenbroucq J. Clarithromycin (CL) in AIDS patients with disseminated M avium Infection: 77 patients. 1st International Conference on the Macrolides, Azalides and Streptogramins. Santa Fe, New Mexico, 1992Google Scholar

  • Dautzenberg B, Truffot C, Legris S, Meyohas M-C, Berlie HC, et al. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. American Review of Respiratory Disease 144: 564–569, 1991PubMedCrossRefGoogle Scholar

  • Del Sel CM, Casellas JM, Farinati A, Iribarren MA. Utilization de claritromicina en el tratamiento de la sinusitis maxilar aguda. Prénsa Médica Argentina 77: 50–54, 1990Google Scholar

  • Derouin F, Chastang C. Activity in vitro against Toxoplasma gon-dii of azithromycin and clarithromycin alone and with pyri-methamine. Journal of Antimicrobial Chemotherapy 25: 708–711, 1990PubMedCrossRefGoogle Scholar

  • Dette GA, Knothe H, Koulen G. Comparative in vitro activity, serum binding and binding activity interactions of the macrolides A-56 268, RU-28965, erythromycin and josamycin. Drugs Under Experimental and Clinical Research 13: 567–576, 1987PubMedGoogle Scholar

  • Dubnau D. Translational attenuation: the regulation of bacterial resistance to the macrolide-lincosamide-streptogramin B antibiotics. CRC Critical Reviews in Biochemistry 16: 103–132, 1984PubMedCrossRefGoogle Scholar

  • Dubois J, Saint-Pierre C. Safety and efficacy of clarithromycin and amoxicillin in the treatment of patients with acute maxillary sinusitis. 17th International Congress of Chemotherapy. Berlin, 1991Google Scholar

  • Dubois J, St Pierre C, Prokocimer P. Treatment of community-acquired pneumonia: a comparison of clarithromycin and erythromycin. 30th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Georgia, October, 1990Google Scholar

  • Eliopoulos GM, Reiszner E, Ferraro MJ, Moellering RC. Comparative in-vitro activity of A-56268 (TE-031), a new macrolide antibiotic. Journal of Antimicrobial Chemotherapy 21: 671–675, 1988Google Scholar

  • Etoh T, Matsuyama T, Iwata M, Watanabe R, Ishibashi Y. Pre-clinical and clinical studies on TE-031 (A-56268) in the field of dermatology. Chemotherapy 36: 943–949, 1988Google Scholar

  • FDC Reports. Abbott’s clarithromycin clears advisory committee for use in women of childbearing potential; Legionnaire’s Disease indication voted down, pp. 9–10, July 22, 1991Google Scholar

  • Fernandes PB. The macrolide revival: thirty five years after erythromycin. Antimicrobic Newsletter 4: 25–36, 1987aCrossRefGoogle Scholar

  • Fernandes PB, Bailer R, Swanson R, Hanson CW, McDonald E, et al. In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrobial Agents and Chemotherapy 30: 865–873, 1986PubMedCrossRefGoogle Scholar

  • Fernandes PB, Hardy D, Bailer R, McDonald E, Pintar J, et al. Susceptibility testing of macrolide antibiotics against Hae-mophilus influenzae and correlation of in vitro results with in vivo efficacy in a mouse septicemia model. Antimicrobial Agents and Chemotherapy 31: 1243–1250, 1987bPubMedCrossRefGoogle Scholar

  • Fernandes PB, Swanson RN, Hardy DJ, McDonald EJ, Ramer N. Effect of dosing intervals on efficacy of clarithromycin and erythromycin in mouse infection models. Drugs Under Experimental and Clinical Research 14: 441–444, 1988PubMedGoogle Scholar

  • Fernandes PB, Baker WR, Freiberg LA, Hardy DJ, McDonald EJ. New macrolides active against Streptococcus pyogenes with inducible or constitutive type of macrolide-lincosamide-strep-togramin B resistance. Antimicrobial Agents and Chemotherapy 33: 78–81, 1989aPubMedCrossRefGoogle Scholar

  • Fernandes PB, Hardy DJ, McDaniel D, Hanson CW, Swanson RN. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrobial Agents and Chemotherapy 33: 1531–1534, 1989bPubMedCrossRefGoogle Scholar

  • Fernandes-Martin J, Leport C, Morlat P, Meyohas MC, Chauvin JP, et al. Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS. Antimicrobial Agents and Chemotherapy 35: 2049–2052; 1991CrossRefGoogle Scholar

  • Ferrero JL, Bopp BA, Marsh KC, Quigley SC, Johnson MJ, et al. Metabolism and disposition of clarithromycin in man. Drug Metabolism and Disposition 18: 441–446, 1990PubMedGoogle Scholar

  • Floyd-Reising S, Hindier JA, Young LS. In vitro activity of A-56268 (TE-031), a new macrolide antibiotic, compared with that of erythromycin and other antimicrobial agents. Antimicrobial Agents and Chemotherapy 31: 640–642, 1987PubMedCrossRefGoogle Scholar

  • Franzblau SC, Hastings RC. In vitro and in vivo activities of macrolides against Mycobacterium leprae. Antimicrobial Agents and Chemotherapy 32: 1758–1762, 1988PubMedCrossRefGoogle Scholar

  • Fraschini F. Clinical efficacy and tolerance of two new macrolides, clarithromycin and josamycin, in the treatment of patients with acute exacerbations of chronic bronchitis. Journal of International Medical Research 18: 171–176, 1990PubMedGoogle Scholar

  • Fraschini F, Scaglione F, Pintucci G, Maccarinelli G, Dugnani S, et al. The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans. Journal of Antimicrobial Chemotherapy 27(Suppl. A): 61–65, 1991PubMedCrossRefGoogle Scholar

  • Fuchi I, Noda K. TE-031 (A-56268) in chlamydial infections during the perinatal period. Chemotherapy 36: 891–894, 1988Google Scholar

  • Fujimaki Y, Kawamura S, Watanabe H. Clinical study on TE-031 (A-56268) in otorhinolaryngology. Chemotherapy 36: 895–899, 1988Google Scholar

  • Furukawa S, Okada T. A clinical evaluation of clarithromycin in the treatment of pediatric infections. Japanese Journal of Antibiotics 42: 420–422, 1989PubMedGoogle Scholar

  • Futterman M, Drnec J. Safety and efficacy of clarithromycin compared with erythromycin in the treatment of community-acquired pneumonia. 30th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Georgia, 1990Google Scholar

  • Gan VN, Chu SY, Kusmiesz HT, Nelson JD, Janousky SR, et al. Single and multi-dose pharmacokinetics in children of clarithromycin granules for children. 1st International Conference on the Macrolides, Azalides and Streptogramins. Santa Fe, New Mexico, 1992Google Scholar

  • Gelber RH, Siu P, Murray LP, Tsang M, Prokocimer P, et al. Clarithromycin at very low levels and on intermittent administration consistently inhibits the growth of M. leprae in mice. 1st International Conference on the Macrolides, Azalides and Streptogramins. Santa Fe, New Mexico, 1992Google Scholar

  • Gelber RH, Siu P, Tsang M, Murray LP. Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice. Antimicrobial Agents and Chemotherapy 35: 760–763, 1991PubMedCrossRefGoogle Scholar

  • Gevaudan M-J, Bollet C, Mallet M-N, de Micco P. Action desantibiotiques sur des variants pigmentés ou non Pigmentés de Mycobacterium avium-intracellulare. Pathologie Biologie 39: 429–435, 1991aPubMedGoogle Scholar

  • Gevaudan M-J, Bollet C, Mallet M-N, (de) Micco P. Mesure de l’activité intra-macrophagique d’associations d’antibiotiques vis-à-vis de Mycobacterium marinum. Pathologie Biologie 39: 436–441, 1991bPubMedGoogle Scholar

  • Gorzynski EA, Gutman SI, Allen W. Comparative antimycobac-terial activities of difloxacin, temafloxacin, enoxacin, peflox-acin, reference fluoroquinolones, and a new macrolide, clarithromycin. Antimicrobial Agents and Chemotherapy 33: 591–592, 1989PubMedCrossRefGoogle Scholar

  • Graham DY, Opekun AR, Klein PD, Drnec J. Clarithromycin for the eradication of H, pylori. 1st International Conference on the Macrolides, Azalides and Streptogramins. Santa Fe, 1992Google Scholar

  • Grosset JH, Truffot-Pernot C, Ji B. Effect of pH on in vitro potency of clarithromycin against mycobacterium avium complex. 1st International Conference on the Macrolides, Azalides and Streptogramins. Santa Fe, New Mexico, 1992Google Scholar

  • Gu JW, Scully BE, Neu HC. Bactericidal activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae and streptococcal pathogens. Journal of Clinical Pharmacology 31: 1146–1150; 1991PubMedGoogle Scholar

  • Guay DRP, Craft JC. Comparative safety and efficacy of clarithromycin and ampicillin in the treatment of out-patients with acute bacterial exacerbation of chronic bronchitis. Journal of Internal Medicine 231: 295–301, 1992PubMedCrossRefGoogle Scholar

  • Gupta S, Northcutt VJ, Prokocimer P, Craft JC. Comparative efficacy and safety of clarithromycin and ampicillin in the treatment of acute bacterial exacerbations of chronic bronchitis. 30th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Georgia, October, 1990Google Scholar

  • Gupta S, Siepman N. Comparative safety and efficacy of clarithromycin versus reference agents in the treatment of mild to moderate bacterial skin or skin structure infections (SSSI). 1st International Conference on the Macrolides, Azalides and Streptogramins. Santa Fe, New Mexico, 1992Google Scholar

  • Hamedani P, Hafeez S, Bachand Jr R, Dawood G, Quereshi S, et al. The safety and efficacy of clarithromycin in patients with Legionella pneumonia. Chest 100: 1503–1506; 1991PubMedCrossRefGoogle Scholar

  • Hanawa S, Yagi K, Takahashi H. TE-031 (A-56268) in treatment of skin infections. Chemotherapy 36: 950–954, 1988Google Scholar

  • Hanson CW, Bailer R, Gade, E, Rode RA, Fernandes PB. Regression analysis, proposed interpretative zone size standards and quality control guidelines for a new macrolide antimicrobial agent, A-56268 (TE-031). Journal of Clinical Microbiology 25: 1079–1082, 1987PubMedGoogle Scholar

  • Hara K, Hirota M, Kohno S, Hayashi T, Suyama N, et al. Doubleblind comparative study on TE-031 (clarithromycin) and MOM (midecamycin acetate) in treatment of pneumonia. Chemotherapy 37: 200–225, 1989aGoogle Scholar

  • Hara K, Hirota M, Kohno S, Hayashi T, Suyama N, et al. Doubleblind comparative study on TE-031 (clarithromycin) and ce-faclor (CCL) in the treatment of chronic respiratory tract infections. Chemotherapy 37: 314–332, 1989bGoogle Scholar

  • Hardy DJ, Hanson CW, Hensey DM, Beyer JM, Fernandes PB. Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones. Journal of Antimicrobial Chemotherapy 22: 631–636, 1988aPubMedCrossRefGoogle Scholar

  • Hardy DJ, Hensey DM, Beyer JM, Vojtko C, McDonald EJ, et al. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrobial Agents and Chemotherapy 32: 1710–1719, 1988bPubMedCrossRefGoogle Scholar

  • Hardy DJ, Swanson RN, Rode RA, Marsh K, Shipkowitz NL, et al. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrobial Agents and Chemotherapy 34: 1407–1413, 1990PubMedCrossRefGoogle Scholar

  • Hatano H, Wakamatsu K. TE-031 (A-56268) in ophthalmology. Chemotherapy 36: 1109–1113, 1988Google Scholar

  • Hattori K, Higashino H, Takebe A, Sato Y, Takedatsu M, et al. Clinical study of clarithromycin, a new macrolide antibiotics, in children. Japanese Journal of Antibiotics 42: 371–380, 1989PubMedGoogle Scholar

  • Hayakawa F, Kuno K, Nakao Y, Yamamoto N, Ishikawa H, et al. Laboratory and clinical studies on clarithromycin in the field of pediatrics. Japanese Journal of Antibiotics 42: 324–338, 1989PubMedGoogle Scholar

  • Hayashi I, Ohnuma K. Clinical examination of TE-031 (A-56268) in respiratory tract infection. Chemotherapy 36: 553–557, 1988Google Scholar

  • Hisadome H, Nomoto S, Tashiro M. TE-031 tablets in cutaneous infections. Chemotherapy 36: 996–1001, 1988Google Scholar

  • Hoppe JE, Eichhorn A. Activity of new macrolides against Bor-detella pertussis and Bordetella parapertussis. European Journal of Clinical Microbiology and Infectious Diseases 8: 653–654, 1989CrossRefGoogle Scholar

  • Hughes WT, Killmar JT. Synergistic anti-Pneumocystis carinii effects of clarithromycin and sulphamethoxazole. 1st International Conference on the Macrolides, Azalides and Streptogramins. Santa Fe, 1992Google Scholar

  • Ikeda M, Yamamoto Y, Tamaki H, Arata J. TE-031 (A-56268) in dermatology. Chemotherapy 36: 984–988, 1988Google Scholar

  • Ito S, Mayumi M, Mikawa H. Clinical evaluation of clarithromycin in pediatric patients. Japanese Journal of Antibiotics 42: 343–351, 1989aPubMedGoogle Scholar

  • Ito Y, Komeda H, Kobayashi K, Kanematsu M, Ban Y, et al. TE-031 (A-56268) against gonococcal and non-gonococcal ur-ethritis. Chemotherapy 36: 832–837, 1988bGoogle Scholar

  • Iwai N, Taneda Y, Miyazu M, Nakamura H, Kasai K. Basic and clinical studies on clarithromycin in pediatrics. Japanese Journal of Antibiotics 42: 304–322, 1989PubMedGoogle Scholar

  • Iwase M, Kimura Y, Nagumo M. TE-031 (A-56268) in acute odontogenic infection of the oral region. Chemotherapy 36: 1082–1085, 1988Google Scholar

  • Izumikawa K, Koteda T, Sakamoto Y, Sawatari K. Clinical study on TE-031 (A-56268) in treatment of respiratory tract infections. Chemotherappy 36: 729–736, 1988Google Scholar

  • Jenkinson S, Anzueto A, Smith B, Thakkar T. Clarithromycin compared with cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis. 1st International Conference on the Macrolides, Azalides and Streptogramins, Santa Fe, New Mexico, 1992Google Scholar

  • Ji B, Jamet P, Bobin P, Grosset JH. Powerful bactericidal activities of clarithromycin and/or minocycline against M leprae in man. 1st International Conference on the Macrolides, Azalides and Streptogramins. Santa Fe, New Mexico, 1992aGoogle Scholar

  • Ji B, Lounis L, Truffot-Pernot C, Grosset JH. In vitro activities of clarithromycin-containing double- or triple-drug combinations against Mycobacterium avium complex. 1st International Conference on the Macrolides, Azalides and Streptogramins, Santa Fe, New Mexico, 1992bGoogle Scholar

  • Ji B, Perani EG, Grosset JH. Effectiveness of clarithromycin and minocycline alone and in combination against Mycobacterium leprae infection in mice. Antimicrobial Agents and Chemotherapy 35: 579–581, 1991.PubMedCrossRefGoogle Scholar

  • Jones RN, Erwin ME, Barrett MS. In vitro activity of clarithromycin (TE-031, A-67268) and 14-0H clarithromycin alone and in combination against Legionella species. European Journal of Clinical Microbiology and Infectious Diseases 9: 846–848, 1990CrossRefGoogle Scholar

  • Jones RN, Hoover W, Barrett M. Contribution of the 14-OH metabolite to the perceived spectrum of in vitro activity: validation of interpretive guidelines for clarithromycin laboratory testing. 1st International conference on the macrolides, azalides and streptogramins. Santa Fe, New Mexico, January 1992.Google Scholar

  • Jorgensen JH, Maher LA, Howell AW. Activity of clarithromycin and its principal human metabolite against Haemophilus in-fluenzae. Antimicrobial Agents and Chemotherapy 35: 1524–1526, 1991PubMedCrossRefGoogle Scholar

  • Kakegawa T, Ogawa T, Hirose S. Mode of inhibition of protein synthesis by TE-031 (A-56268). Chemotherapy 36: 123–128, 1988Google Scholar

  • Kakegawa T, Hirose S. Mode of inhibition of protein synthesis by metabolites of clarithromycin. Chemotherapy 38: 317–323, 1990Google Scholar

  • Karma P, Pukander J, Penttila M, Ylikoski J, Savolainen S, et al. The comparative efficacy and safety of clarithromycin and amoxycillin in the treatment of outpatients with acute maxillary sinusitis. Journal of Antimicrobial Chemotherapy 27(Suppl. A): 83–90, 1991PubMedCrossRefGoogle Scholar

  • Katahira J, Fukada T, Kumada T, Shimizu K. Basic and clinical studies on TE-031 (A-56268). Chemotherapy 36: 594–599, 1988Google Scholar

  • Kato M, Hayashi Y, Matsuura T, Ito G, Tashiro T, et al. Transfer of TE-031 (A-56268) into solution for bronchoalveolar lavage and clinical study. Chemotherapy 36: 652–659, 1988Google Scholar

  • Kawamura N, Ohhara A, Shiramizu M, Kawashima T, Ohkoshi M. Clinical effect of TE-031 (A-56268) on urethritis. Chemotherapy 36: 815–821, 1988Google Scholar

  • Kawamura S, Takasaka T, Kobayashi T, Ikeda K, Endo S, et al. Double-blind comparative clinical study on TE-031 and jos-amycin in treatment of lacunar tonsilitis. Jibi to Rinsho 35: 134–151; 1989Google Scholar

  • Kimura Y, Kukita A. TE-031 (A-56268) in dermatological infections. Chemotherapy 36: 938–942, 1988Google Scholar

  • Kishi M, Yamada D, Nasu Y, Tsugawa M, Kumon H, et al. TE-031 in urethritis. Chemotherapy 36: 842–849, 1988Google Scholar

  • Koga H, Inoue Y, Taira K, Mashimoto H, Masaki M et al. Laboratory and clinical studies on TE-031 (A-56268). Chemotherapy 36: 698–714, 1988Google Scholar

  • Kohno S, Koga H, Yamaguchi K, Masaki M, Inoue Y, et al. A new macrolide, TE-031 (A-56268), in treatment of experimental Legionnaires’ disease. Journal of Antimicrobial Chemotherapy 24: 397–405, 1989aPubMedCrossRefGoogle Scholar

  • Kohno Y, Yoshida H, Suwa T, Suga T. Comparative pharmaco-kinetics of clarithromycin (TE-031), a new macrolide antibiotic, and erythromycin in rats. Antimicrobial Agents and Chemotherapy 33: 751–756, 1989bPubMedCrossRefGoogle Scholar

  • Kohno Y, Yoshida H, Suwa T, Suga T. Uptake of clarithromycin by rat lung cells. Journal of Antimicrobial Chemotherapy 26: 503–513, 1990aPubMedCrossRefGoogle Scholar

  • Kohno Y, Ohta K, Suwa T, Suga T. Autobacteriographic studies of clarithromycin and erythromycin in mice. Antimicrobial Agents and Chemotherapy 34: 562–567, 1990bPubMedCrossRefGoogle Scholar

  • Kojima H, Mori C. TE-031 (A-56268) against gonococcal and chlamydial infections. Chemotherapy 36: 793–798, 1988Google Scholar

  • Krogstad DJ, Moellering Jr RC. Antimicrobial combinations. In Lorian V (Ed) Antibiotics in laboratory medicine, pp. 537–595, Williams & Wilkins, Baltimore, 1986Google Scholar

  • Kudo K, Komase Y, Kowada A, Kabe J. A clinical study of oral TE-031 (A-56268) in respiratory infections. Chemotherapy 36: 617–622, 1988Google Scholar

  • Kumamoto Y, Sakai S, Tsunekawa T, Hayashi K, Tabata S, et al. Basic and clinical studies on efficacy of TE-031 (A-56268) in treatment of male urethritis and cervicitis. Chemotherapy 36: 752–773, 1988Google Scholar

  • Larrey D, Funck-Brentano C, Breil P, Vitaux J, Theodore C, et al. Effects of erythromycin on hepatic drug-metabolizing enzymes in humans. Biochemical Pharmacology 32: 1063–1068, 1983aPubMedCrossRefGoogle Scholar

  • Larrey D, Tinel M, Pessayre D. Formation of inactive cyto-chrome P-450 Fe(II)-metabolite complexes with several erythromycin derivatives but not with josamycin and mideca-mycin in rats. Biochemical Pharmacology 32: 1487–1493, 1983bPubMedCrossRefGoogle Scholar

  • Levenstein JH. Clarithromycin versus penicillin in the treatment of streptococcal pharyngitis. Journal of Antimicrobial Chemotherapy 27(Suppl. A): 67–74, 1991PubMedCrossRefGoogle Scholar

  • Liebers DM, Baltch AL, Smith RP, Hammer MC, Conroy JV. Susceptibility of Legionella pneumophila to eight antimicrobial agents including four macrolides under different assay conditions. Journal of Antimicrobial Chemotherapy 23: 37–41, 1989PubMedCrossRefGoogle Scholar

  • Logan MN, Ashby JP, Andrews JM, Wise R. The in-vitro activity and disc susceptibility testing of clarithromycin and its 14-hy-droxy metabolite. Journal of Antimicrobial Chemotherapy 27: 161–170, 1991PubMedCrossRefGoogle Scholar

  • Mandell L, Ehsan M. Effects of antibiotic antifungal and antiviral drugs on neutrophil function. Abstract 168. 12th International Congress on Chemotherapy, Florence, 1981Google Scholar

  • Marchi E. Comparative efficacy and tolerability of clarithromycin and amoxycillin in the treatment of out-patients with acute maxillary sinusitis. Current Medical Research and Opinion 12: 19–24, 1990PubMedCrossRefGoogle Scholar

  • Martin R, Rank R, Persson K, Drnec J, Bates J. Chlamydia pneumonia (TWAR): comparative efficacy of clarithromycin and erythromycin. 30th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Georgia, October, 1990Google Scholar

  • Matsuda S, Suzuki M, Miyazaki R, Takase S, Oh K. TE-031 (A-56268) in obstetrics and gynecology — therapeutic efficacy in gonococcal and chlamydial cervicitis. Chemotherapy 36: 875–879, 1988aGoogle Scholar

  • Matsuda S, Matsumoto T, Urabe H. TE-031 (A-56268) in bacterial infections of the skin. Chemotherapy 36: 989–993, 1988bGoogle Scholar

  • McDonald PJ, Craig WA, Kunin CM. Persistent effect of antibiotics on Staphylococcus aureus after exposure for limited periods of time. Journal of Infectious Diseases 135: 217–223, 1977PubMedCrossRefGoogle Scholar

  • Meguro H, Arimasu O, Hiruma F, Sugamata K, Sugie N, et al. Clinical evaluation of clarithromycin, a new macrolide antibiotic in children. Japanese Journal of Antibiotics 42: 255–262, 1989PubMedGoogle Scholar

  • Mehtar S, Macklin JL, Coles SJ, Shuga M, Blakemore PH. Clinical efficacy of clarithromycin compared with amoxycillin and ce-faclor in the treatment of bronchitis. 17th International Congress on Chemotherapy, Berlin, Federal Republic of Germany, 1991Google Scholar

  • Miki F, Ikuno Y, Inoue E, Murata A, Tanizawa S, et al. Clinical study on TE-031 (A-56268). Chemotherapy 36: 666–672, 1988Google Scholar

  • Miyazaki Y, Nishizono H, Matsuzaki N, Tsurumaru H, Matsune S, et al. TE-031 (A-56268) for infectious diseases in the otor-hinolaryngological field. Chemotherapy 36: 926–934, 1988Google Scholar

  • Mizushima Y, Hiratsuka H. General clinical study on TE-031 (A-56268). Chemotherapy 36: 452–499, 1988Google Scholar

  • Motohiro T, Sakata Y, Kuroiwa Y, Aramaki M, Oda K, et al. Clinical study on clarithromycin granule and tablet in the field of pediatrics. Japanese Journal of Antibiotics 42: 423–462, 1989aPubMedCrossRefGoogle Scholar

  • Motohiro T, Yoshinaga Y, Sasaki H, Oda K, Aramaki M, et al. Pharmacokinetics of clarithromycin granule and tablet in children. Japanese Journal of Antibiotics 42: 465–491, 1989bPubMedGoogle Scholar

  • Murakami S, Igarashi T, Yamashiro Y, Fujita R, Suzuki R, et al. Clinical effect of TE-031 (A-56268) on male urethritis. Chemotherapy 36: 784–787, 1988Google Scholar

  • Muranaka K, Isomatsu Y, Kawada Y, Shimazu R. Clinical study on TE-031 (A-56268) against male urethritis. Chemotherapy 36: 827–831, 1988Google Scholar

  • Naik S, Ruck R. In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. Antimicrobial Agents and Chemotherapy 33: 1614–1616, 1989PubMedCrossRefGoogle Scholar

  • Nakayama I, Yamaji E, Kawamura H, Kawaguchi H, Akieda Y, et al. Clinical study on TE-031 (A-56268), a new macrolide antibiotic, in skin and soft-tissue infections in the field of surgery. Chemotherapy 36: 1005–1028, 1988Google Scholar

  • NCCLS, Thornsberry C, et al. (Eds) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. National Committee for Clinical Laboratory Standards publication M7-A, NCCLS, Villanova, Pa, 1985Google Scholar

  • Nellans HN, Peterson AC, Peeters TL. Gastrointestinal side effects: clarithromycin superior to azithromycin in reduced smooth muscle binding. International Congress on Antimicrobial Agents and Chemotherapy, 1991Google Scholar

  • Niki Y, Nakajima M, Tsukiyama K, Nakagawa Y, Umeki S, et al. Effect of TE-031 (A-56268), a new oral macrolide antibiotic, on serum theophylline concentration. Chemotherapy 36: 515–520, 1988Google Scholar

  • Nishimura T, Tabuki K, Aoki S, Takagi M. Laboratory and clinical studies of clarithromycin in pediatric fields. Japanese Journal of Antibiotics 42: 353–369, 1989PubMedGoogle Scholar

  • Noguchi M, Yamazaki K, Akita T, Okamoto T, Ito N, et al. TE-031 (A-56268) in obstetric and gynecological infections of Chlamydia trachomatis. Chemotherapy 36: 880–885, 1988Google Scholar

  • Nohara N, Akagi O, Ohara A, Ohkawara A, Kumakiri M, et al. Comparative double-blind clinical trial on TE-031 (A-56268) and erythromycin in superficial suppurative skin and soft tissue infections. Chemotherapy 37: 173–198, 1989Google Scholar

  • Odagiri S, Chiba J, Suzuki K, Murohashi K, Takahashi H, et al. Clinical studies of TE-031 (A-56268) in respiratory tract infection. Chemotherapy 36: 639–651, 1988Google Scholar

  • Ogawa K, Iyozumi K, Harada S. TE-031 (A-56268) in treatment of superficial purulent diseases. Chemotherapy 36: 955–960, 1988Google Scholar

  • Ogura H, Kubota H, Nomura I, Tomoda T, Araki K, et al. Clinical efficacy of clarithromycin in the field of pediatrics. Japanese Journal of Antibiotics 42: 400–410, 1989Google Scholar

  • Ohara A, Akagi O, Kanzaki H, Kanamoto A, Nohara N, et al. TE-031 (A-56268) in the field of dermatology. Chemotherapy 36: 971–977, 1988Google Scholar

  • Ohkawa M, Tokunaga S, Hisazumi H, Ueno K, Watanabe K. Antibacterial activity of TE-031 (A-56268), a new macrolide antibiotic against clinical isolates of Neisseria gonorrhoeae, and clinical evaluation of TE-031 in male urethritis. Chemotherapy 36: 822–826, 1988Google Scholar

  • Ohta M, Shono S, Hori S, Ohnuki A, Toda K. Clinical efficacy and transfer of TE-031 (A-56268) to blood and skin. Chemotherapy 36: 961–965, 1988Google Scholar

  • Ohtake T, Ogura K, Iwatate I, Suwa T. Assay for TE-031 (A-56268) in body fluids (II). High performance liquid chroma-tography. Chemotherapy 36: 192–197, 1988aGoogle Scholar

  • Ohtake T, Ogura K, Iwatate C, Suwa T. Assay method for TE-031 (A-56268) in body fluids (III). High performance liquid Chromatographic assay method for TE-031 and its metabolites. Chemotherapy 36: 916–920, 1988bGoogle Scholar

  • Okazaki T, Machida T, Onodera S, Kiyota H, Goto H. TE-031 (A-56268) against male urethritis. Chemotherapy 36: 788–792, 1988Google Scholar

  • Olsson-Liljequist B, Hoffman B-M. In vitro activity of clarithromycin combined with its 14-hydroxy metabolite A-626671 against Haemophilus influenzae. Antimicrobial Chemotherapy 27(Suppl. A): 11–17, 1991CrossRefGoogle Scholar

  • O’Neill SJ, Millar ED, Coles SJ, Bachand RT. Safety and efficacy of clarithromycin in the treatment of acute mild to moderate respiratory tract infections. Irish Medical Journal 84: 33–35, 1991PubMedGoogle Scholar

  • Ono Y, Haga T, Ueda Y, Baba M, Oyatsu I et al. Effect of TE-03 1 (A-56268) on phagocytic cell function. Chemotherapy 36: 608–616, 1988Google Scholar

  • Ooishi M, Sakaue F, Oomomo A, Tazawa H. TE-031 (A-56268) in the treatment of ocular infections. Chemotherapy 36: 1101–1108, 1988Google Scholar

  • Orme M, Back DJ, Tjia J, Martin C, Millar E, et al. The lack of interaction between clarithromycin and oral contraceptive steroids. British Journal of Clinical Pharmacology 31: 229P, 1991Google Scholar

  • Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clinical Pharmacokinetics 23: 106–131, 1992PubMedCrossRefGoogle Scholar

  • Pichotta P, Gupta S, Prokocimer P, Pernet A. The overall safety of oral clarithromycin in comparative clinical studies. 30th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Georgia, October 1990 Poirier R. Comparative study of clarithromycin and roxithro-mycin in the treatment of community-acquired pneumonia. Journal of Antimicrobial Chemotherapy 27(Suppl. A): 109–116, 1991Google Scholar

  • Polis MA, Haneiwich S, Kovacs JA, Davey RT, Walker RE, et al. Dose escalation study to determine the safety, maximally tolerated dose (MTD) and pharmacokinetics of clarithromycin (clari) with zidovudine (zdv) in HIV-infected patients. International Congress on Antimicrobial Agents and Chemotherapy, 1991Google Scholar

  • Powell M, Chen H-Y, Williams JD. Synergy between clarithromycin and its 14-OH metabolite against Haemophilus influ-enzae. 30th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Georgia, October 1990Google Scholar

  • Preac-Mursic V, Wilske B, Shierz G, Süβ E, Groβ B. Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi. European Journal of Clinical Microbiology and Infectious Diseases 8: 651–653, 1989CrossRefGoogle Scholar

  • Prokocimer P. An evaluation of clarithromycin and cefixime for lower respiratory tract infections. 1st International Conference on the Macrolides, Azalides and Streptogramins, Santa Fe, New Mexico, 1992Google Scholar

  • Ramasesh N, Krahenbuhl JL, Hastings RC. In vitro effects of antimicrobial agents on Mycobacterium leprae in mouse peritoneal macrophages. Antimicrobial Agents and Chemotherapy 33: 657–662, 1989PubMedCrossRefGoogle Scholar

  • Rastogi N, Labrousse V. Extracellular and intracellular activities of clarithromycin used alone and in association with etham-butol and rifampin against Mycobacterium avium complex. Antimicrobial Agents and Chemotherapy 35: 462–470, 1991PubMedCrossRefGoogle Scholar

  • Rehg JE. Anticryptosporidial activity of macrolides in immu-nosuppressed rats. 1st International Conference on the Macrolides, Azalides and Streptogramins. Santa Fe, New Mexico, 1992Google Scholar

  • Renaudin H, Bébéar C. Comparative in vitro activity of azith-romycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Urea-plasma urealyticum. European Journal of Clinical Microbiology and Infectious Diseases 9: 838–841, 1990CrossRefGoogle Scholar

  • Richens AS, Chu SY, Sennello LT, Sonders RC. Effect of multiple doses of clarithromycin on the pharmacokinetics of theophyl-line. 30th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Georgia, 1990Google Scholar

  • Ridgway GL, Mumtaz G, Fenelon L. The in-vitro activity of clarithromycin and other macrolides against the type strain of Chlamydia pneumoniae (TWAR). Journal of Antimicrobial Chemotherapy 27(Suppl. A): 43–45, 1991PubMedCrossRefGoogle Scholar

  • Rolston K, Gooch G, Ho D. In-vitro activity of clarithromycin (A-56268; TE-031) against Gram-positive bacteria, Correspondence. Journal of Antimicrobial Chemotherapy 23: 455–457, 1989PubMedCrossRefGoogle Scholar

  • Roszkowski K, Beuth J, Ko HL, Peters G, Pulverer G. Comparative study on the macrolides erythromycin and clarithromycin: antibacterial activity and influence on immune responses. Zentralblatt für Bakteriologie 273: 518–530, 1990PubMedCrossRefGoogle Scholar

  • Ruf B, Shürmann D, Mauch H, Fehrenbach FJ, Pohle HD, et al. Efficacy of clarithromycin (A 56268) in the acute and maintenance treatment of Mycobacterium avium-intracellulare infection in HIV-infected patients. Mikrobiologie und Hygene. American Review of Respiratory Disease 143: A116, 1991Google Scholar

  • Ruf F, Chu SY, Sonders RC, Sennello LT. Effect of multiple doses of clarithromycin on the pharmacokinetics of theophylline. International Conference on Antimicrobial Agents and Chemotherapy. Atlanta, Georgia, 1990Google Scholar

  • Saint-Pierre E, Dubois J, Prokocimer P, Drnec J. An evaluation of clarithromycin and amoxicillin/clavulanate for the treatment of acute maxillary sinusitis. 1st International Conference on the Macrolides, Azalides and Streptogramins. Santa Fe, New Mexico, 1992Google Scholar

  • Saito A, Ishikawa K, Shinohara M, Fukuhara I, Nakayama I, et al. Preclinical and clinical studies on TE-031 (A-56268). Chemotherapy 36: 521–537, 1988aGoogle Scholar

  • Saito A, Shimada J, Ohmori M, Shiba K, Yamaji T, et al. Clinical studies on TE-031 (A-56268). Chemotherapy 36: 576–585, 1988bGoogle Scholar

  • Saito I, Yokozawa M, Ono K, Yamaguchi K, Takahashi K, et al. Basic and clinical studies on TE-031 (A-56268). Chemotherapy 36: 774–783, 1988cGoogle Scholar

  • Sakai K, Ueda T, Hirata S, Ri T, Fujimoto M, et al. Clinical study of TE-031 (A-56268) in surgery. Chemotherapy 36: 1039–1048, 1988Google Scholar

  • Sakurai T, Ezaki Y, Konishi K, Nakai Y. TE-031 (A-56268) in ear-nose-throat infections. Chemotherapy 36: 912–918, 1988Google Scholar

  • Sanda N, Seo K, Seko S, Sumii T, Nakano H, et al. TE-031 (A56268) in genitourinary infections caused by Chlamydia trachomatis. Chemotherapy 36: 850–854, 1988Google Scholar

  • Sano Y, Miyamoto Y, Fukaya K, Oka S, Goto H, et al. Non-clinical and clinical studies on TE-031 (A-56268). Chemotherapy 36: 606–607, 1988Google Scholar

  • Sasaki J, Morishima T, Sakamoto H, Takai H, Ikeshima K, et al. Clinical evaluation of clarithromycin in treatment of acute dental infections. Japanese Journal of Antibiotics 42: 983–1013, 1989PubMedGoogle Scholar

  • Sasaki J, Uematsu M, Sakamoto H, Shiki K, Yamane N, et al. Basic and clinical studies on TE-031 (A-56268) tablets. Chemotherapy 36: 1058–1073, 1988Google Scholar

  • Sawae Y, Kumagai Y, Ishimaru T, Takagi K, Niho Y. Laboratory and clinical studies on TE-031 (A-56268). Chemotherapy 36: 679–697, 1988Google Scholar

  • Scaglione F. Comparison of the clinical and bacteriological efficacy of clarithromycin and erythromycin in the treatment of streptococcal pharyngitis. Current Medical Research and Opinion 12: 25–33, 1990PubMedCrossRefGoogle Scholar

  • Scaglione F, Dugnani S, Demartini G, Saudelli M, Galmozzi G, et al. 1st International Conference on the Macrolides, Azalides and Streptogramins. Santa Fe, New Mexico, 1992Google Scholar

  • Scaglione F, Fraschini F. Distribution of clarithomycin (calr) and its metabolite (14-OH) in therapeutically relevant respiratory tract tissues and fluids. 1st International Conference on the Macrolides, Azalides and Streptogramins. Santa Fe, New Mexico, 1992Google Scholar

  • Schaad U, Siepman N, Northcutt VJ, Janousky S, Craft JC. Clarithromycin in pediatric patients. 1st International Conference on the Macrolides, Azalides and Streptogramins. Santa Fe, New Mexico, 1992Google Scholar

  • Segreti J, Kapell K, Koenig G, Trenholme G. In vitro activity of clarithromycin and 14 OH clarithromycin against TWAR compared to doxycycline. 1st International Conference on the Macrolides, Azalides and Streptogramins. Santa Fe, New Mexico, January 1992Google Scholar

  • Sekiguchi T, Okamoto T, Ohara K, Nishimori M, Kozan S, et al. Clinical observations with clarithromycin in pediatrics. Japanese Journal of Antibiotics 42: 411–419, 1989PubMedGoogle Scholar

  • Shigeoka H, Kosaka H, Kuwahara K, Kamei R, Takii M. Phar-macokinetic and clinical studies on TE-031 (A-56268). Chemotherapy 36: 679–686, 1988Google Scholar

  • Shiiki K, Yamane N. Basic study on TE-031 (A-56268). Chemotherapy 36: 511–514, 1988Google Scholar

  • Shimada T, Goto T, Kawahara M, Sakamoto N, Shimoinaba T, et al. TE-031 (A-56268) in gonorrheal and chlamydial infection. Chemotherapy 36: 868–874, 1988Google Scholar

  • Shinkawa A, Tamura Y, Shimizu K, Miyake H. TE-031 (A-56268) in the field of otorhinolaryngology. Chemotherapy 36: 900–906, 1988Google Scholar

  • Siepman N. Influence of clarithromycin on theophylline levels in patients with bronchial infections. 1st International Conference on the Macrolides, Azalides and Streptogramins. Santa Fe, New Mexico, 1992Google Scholar

  • Soejima R, Niki Y, Hino J, Nakagawa Y, Sumi M, et al. Clinical studies on TE-031 (A-56268). Chemotherapy 36: 673–678, 1988Google Scholar

  • Soyano K, Baba S, Mori Y, Suzuki K, Shimada J, et al. TE-031 (A-56268) in otorhinolaryngology. Chemotherapy 36: 907–911, 1988Google Scholar

  • Spiritus E, Devcich K, Drnec J, Hallwas R. Clarithromycin vs cefaclor for acute exacerbations of bronchitis. 1st International Conference on the Macrolides, Azalides and Streptogramins, Santa Fe, New Mexico, 1992Google Scholar

  • Straneo G, Scarpazza G. Efficacy and safety of clarithromycin versus josamycin in the treatment of hospitalized patients with bacterial pneumonia. Journal of International Medical Research 18: 164–170, 1990PubMedGoogle Scholar

  • Sundberg L. Penetration of clarithromycin into middle ear effusion. 1st International Conference on the Macrolides, Azalides and Streptogramins. Santa Fe, New Mexico, 1992Google Scholar

  • Suwa T, Urano H, Kodama T, Nakamura M, Watanabe T. Metabolic fate of TE-031 (A-56268) VIII. Absorption and excretion in humans (bioassay). Chemotherapy 36: 921–932, 1988aGoogle Scholar

  • Suwa T, Yoshida H, Kohno Y, Yoshitomi S, Ohta K. Metabolicfate of TE-031 (A-56268) III. Absorption, Distribution and excretion of 14C-TE-031 in rats, mice and dogs. Chemotherapy 36: 213–226, 1988bGoogle Scholar

  • Suwa T, Yoshida H, Fukushima K, Nagate T. Metabolic fate of TE-031 (A-56268) I. Comparative pharmacokinetics of TE-031 and erythromycin stearate in rats and mice. Chemotherapy 36: 198–204, 1988cGoogle Scholar

  • Suzuki M, Tagashira N, Hirakawa K, Yajin K, Haràda Y, et al. TE-031 (A-56268) in otorhinolaryngology. Chemotherapy 36: 919–925, 1988Google Scholar

  • Takahashi O, Takeda K. TE-031 (A-56268) in dermatology. Chemotherapy 36: 978–983, 1988Google Scholar

  • Takai H, Ikeshima K, Adachi F, Kishiro H, Koya F, et al. TE-031 (A-56268) in acute infections in the field of oral surgery. Chemotherapy 36: 1049–1057, 1988Google Scholar

  • Takeda H, Miura H, Kawahira M, Kobayashi H, Otomo S, et al. Long-term administration study on TE-031 (A-56268) in treatment of diffuse panbronchiolitis. Kansenshogaku Zasshi 63: 71–78, 1989PubMedGoogle Scholar

  • Takeda H, Oshitani H, Yoneda Y, Kobayashi H. Basic and clinical studies on TE-031 (A-56268). Chemotherapy 36: 569–575, 1988Google Scholar

  • Takii M, Shigeoka H, Ibaragi K, Kuwahara K, Kohno K. Phar-macokinetic study on TE-031 (A-56268) in subjects with various degrees of renal dysfunction. Chemotherapy 37: 15–21, 1989Google Scholar

  • Tanaka M, Ogata N, Matsumoto T, Kumazawa J, Sagiyama K, et al. Preclinical and clinical studies on TE-031 (A-56268) in urinary tract and genital infections. Chemotherapy 36: 855–867, 1988Google Scholar

  • Tayama M, Ichioka T, Hosoda T, Miyao M. Clinical experience with clarithromycin in the pediatric field. Japanese Journal of Antibiotics 42: 388–392, 1989PubMedGoogle Scholar

  • Tinel M, Descatoire V, Larrey D, Loeper J, Labbe G, et al. Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides. Journal of Pharmacology and Experimental Therapeutics 250: 746–751, 1989PubMedGoogle Scholar

  • Tomii M, Kobayashi Y, Fujimori I. Clinical study on TE-031 (A-56268) in internal medicine. Chemotherapy 36: 635–638, 1988Google Scholar

  • Tsutsui T, Haruta T, Kuroki S, Ohkura K-E. A clinical study on clarithromycin especially on its granular form for children, in pediatrics. Japanese Journal of Antibiotics 42: 381–387, 1989PubMedGoogle Scholar

  • Unoura T, Masuda M, Takeuchi K, Itaoh T, Tamura M, et al. Clinical study on TE-031 (A-56268) against respiratory infections. Chemotherapy 36: 544–548, 1988Google Scholar

  • Vallée E, Azoulay-Dupuis E, Swanson R, Bergogne-Bérézin E, Pocidalo J-J. Individual and combined activities of clarithromycin and its 14-hydroxy metabolite in a murine model of Haemophilus influenzae infection. Journal of Antimicrobial Chemotherapy 27(Suppl. A): 31–41, 1991PubMedCrossRefGoogle Scholar

  • Vogel F. Efficacy and tolerability of clarithromycin in the short-course treatment of acute respiratory tract infections. Drug Investigation 3: 205–209, 1991CrossRefGoogle Scholar

  • Vozeh S, Schmidlin. Pharmacokinetic drug data. In Speight T.M. (Ed.) Avery’s Drug Treatment 3rd ed., p. 1368, ADIS Press Limited, New Zealand, 1987Google Scholar

  • Waites KB, Cassell GH, Canupp KC, Fernandes PB. In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones. Antimicrobial Agents and Chemotherapy 32: 1500–1502, 1988PubMedCrossRefGoogle Scholar

  • Wallace Jr RJ, Brown BA, Onyi GO. Activity of clarithromycin (CL) against slow-growing nontuberculous mycobacteria using a broth microdilution MIC system. 1st International Conference on the Macrolides, Azalides and Streptogramins. Santa Fe, New Mexico, January 1992aGoogle Scholar

  • Wallace Jr RJ, Tanner D, Brennan PJ, Brown BA, Craft JC et al. Preliminary results of an open noncomparative trial of clarithromycin (CL) in the therapy of (disseminated) infection due to Mycobacterium chelonae subsp. chelonae (Mcc). 1st International Conference on the Macrolides, Azalides and Streptogramins, Santa Fe, New Mexico, January 1992bGoogle Scholar

  • Watanabe K, Koyama M. Preclinical and clinical studies on TE-031 (A-56268). Chemotherapy 36: 623–629, 1988Google Scholar

  • Weisblum B. Inducible erythromycin resistance in bacteria. British Medical Bulletin 40: 47–53, 1984PubMedGoogle Scholar

  • Weisblum B, Holder SB, Hailing SM. Deoxyribonucleic acid sequence common to staphylococcal and streptococcal plasmids which specify erythromycin resistance. Journal of Bacteriology 138: 990–998, 1979PubMedGoogle Scholar

  • Weisblum B, Siddhikol C, Lai CJ, Demohn V. Erythromycin-inducible resistance in Staphylococcus aureus: requirements for induction. Journal of Bacteriology 106: 835–847, 1971PubMedGoogle Scholar

  • Wettengel R. A double blind, randomised study of low dose clarithromycin versus cefaclor for the treatment of lower respiratory tract infection. 17th International Congress on Chemotherapy, Berlin, Federal Republic of Germany, 1991Google Scholar

  • Wollmer P, Pride NB, Rhodes CG, Sanders A, Pike VW, et al. Measurement of pulmonary erythromycin concentration in patients with lobar pneumonia by means of positron tomography. Lancet 2: 1361–1364, 1982PubMedCrossRefGoogle Scholar

  • Yabuuchi E, Kohbata S, Ikedo M. Antibacterial activity of TE-031 (A-56268) against Legionella species. Chemotherapy 36: 88–94, 1988Google Scholar

  • Yamagoe M, Osada T, Nakanome M, Inoue T, et al. Clinical study on TE-031 (A-56268) against infections of the urinary tract and genitalia. Chemotherapy 36: 803–814, 1988Google Scholar

  • Yamane G, Sekigawa K, Sasaki K, Yamaguchi M, Noma H. TE-031 (A-56268) in oral surgery. Chemotherapy 36: 1074–1081, 1988Google Scholar

  • Yanagi F, Kusama M, Tanaka K, Enomoto S. TE-031 (A-56268) in acute dental infections in the stomatognathic area. Chemotherapy 36: 1086–1090, 1988Google Scholar

  • Yanagishima M, Yanai M, Yanagi T, Tsuji Y, Nakayama N, et al. Pharmacokinetic and clinical studies of clarithromycin in the pediatric field. Japanese Journal of Antibiotics 42: 475–511, 1989CrossRefGoogle Scholar

  • Yasuda J, Yamamoto T, Kanao M, Okada H. TE-031 (A-56268) in Trachomatis infections in obstetrics and gynecology. Chemotherapy 36: 886–890, 1988Google Scholar

  • Yokota T, Suzuki E, Arai K. TE-031 (A-56268), a new macrolide, its in vitro antibacterial activity, synergy of bactericidal effect with serum complement and mouse cultured macrophages, and incorporation into leucocytes. Chemotherapy 36: 59–70, 1988Google Scholar

  • Yoshii T, Ichii M, Kobayashi S, Sano E, Utoh K, et al. Basic and clinical studies on TE-031 (A-56268) in oral surgery. Chemotherapy 36: 1091–1100, 1988Google Scholar

  • Yoshii T, Motoji S, Nakasuji K, Ichii M, Kobayashi S, et al. Basic study on TE-031 (A-56268) in oral surgery. Chemotherapy 37: 1085–1089, 1989Google Scholar

  • Yura J, Shinagawa N, Mizuno A, Mashita K, Hori K, et al. Clinical study on TE-031 (A-56268) in surgery. Chemotherapy 36: 1029–1038, 1988Google Scholar


Source: https://link.springer.com/article/10.2165/00003495-199244010-00009


BUY NOW For Sale 70%!
buy viagra

2015 Azithromycin-Resistant Neisseria gonorrhea. - King County Azithromycin side effects after stopping prednisone

Wechselwirkung pille azithromycin 500 Cardiac risks associated with antibiotics: azithromycin and levofloxacin
Wechselwirkung pille azithromycin 500 Azithromycin over the counter for chlamydia - Trusted Pharmacy
Wechselwirkung pille azithromycin 500 Chewable Vitamin C Tablets 1000mg Simply Supplements
Wechselwirkung pille azithromycin 500 What are Amphibians? - Amphibian Ark-Saving Endangered
Wechselwirkung pille azithromycin 500 Wolfdog - Wikipedia
Wechselwirkung pille azithromycin 500 AZIWOK 250MG TABLET Medbharat
Wechselwirkung pille azithromycin 500 Cat-scratch Disease - American Family Physician
Wechselwirkung pille azithromycin 500 Lopid 600 mg dosis ibuprofeno use of lamotrigine in pregnancy
BUY NOW For Sale 70%!
buy viagra